JPRN-jRCT2080223962已完成2 期
An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Have a diagnosis of RA according to 2010 ACR/ EULAR rheumatoid arthritis (RA) classification criteria
- •-Have an inadequate response to MTX
排除标准
- •-Have been treated with conventional synthetic disease-modifying anti-rheumatic drug, except for MTX, within 28 days prior to randomization
- •-Have an inadequate response to biologic disease-modifying anti-rheumatic drug or have been treated with 2 biologic treatment
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipivoxil for Chronic Hepatitis B and having Persistent Viral Replication. Estudio aleatorizado de fase 2 a doble ciego para evaluar la eficacia, seguridad y tolerabilidad de la monoterapia de tenofovir disoproxil fumarato (DF) en comparación con la terapia combinada de emtricitabina más tenofovir DF a dosis fija, en pacientes que reciben adefovir dipivoxil en la actualidad para el tratamiento de la hepatitis B crónica y presentan replicación viral persistenteChronic Hepatitis B Hepatitis B crónicaMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2005-003136-22-ESGilead Sciences Incorporated90
进行中（未招募）
不适用
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipivoxil for Chronic Hepatitis B and having Persistent Viral Replication.EUCTR2005-003136-22-DEGilead Sciences Incorporated90
进行中（未招募）
不适用
A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Advanced Non Small Cell Lung Cancer previously not treatedMedDRA version: 6.1Level: PTClassification code 10029522EUCTR2004-000379-32-ITASTRAZENECA200
进行中（未招募）
不适用
A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) - 6474IL0007on Small Cell Lung CancerEUCTR2004-000379-32-FIAstraZeneca AB200
进行中（未招募）
1 期
A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLCnon small cell lung cancerEUCTR2004-000379-32-ESAstraZeneca AB200